5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Syncom Formulations (India) Ltd.

•
sfil.inBSE: 524470NSE: SYNCOMF
Market Cap₹ 1,817 Cr.
Current Price
High / Low₹ 23 / 10
Stock P/E21.2
Book Value₹ 5
Price to Book4.52
Dividend Yield0.00 %
ROCE18.8 %
ROE15.7 %
Face Value₹ 1

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2025 • Pharmacutical Drugs & Formulations: 97.5% • Trading of Comodities: 1.7% • Renting of Property: 0.8%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company has delivered good profit growth of 36.7% CAGR over last 5 years
  • Company is almost debt free
  • Latest quarter profit grew 57.7% YoY, showing strong momentum
  • Company has consistently been profitable over the last 5 years
  • Company has delivered good sales growth of 20.4% CAGR over last 5 years

CONS

  • A large part of profit comes from other income (26.6% of PBT)
  • Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.30x)
  • Recurring exceptional / one-off items are inflating headline profit
  • Though reporting repeated profits, the company pays out little dividend (0.0%)

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY 500NIFTY LARGEMIDCAP 250NIFTY 100NIFTY 200
S.No.Name
1.SUNPHARMA1864.0036.98447236.040.862901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9405.0085.36249673.200.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4928.4085.95187460.490.77566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1118.0024.71111520.930.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1380.0033.08111484.470.94785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1936.0095.67104604.450.10362.07123.942026.3129.1018.2031.50
7.AUROPHARMA1669.0025.8796030.570.241032.0325.229150.3517.4412.7620.54
8.DRREDDY1140.8029.5595220.280.70435.60-69.108099.80-5.2113.7510.63
9.LUPIN2075.0017.1694882.670.871416.9816.018276.8934.2828.8629.59
10.MANKIND2246.0045.4292769.930.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2417.0037.9468213.700.10482.83927.884018.4831.3520.3520.03
12.SYNCOMF19.3321.241817.020.0024.8557.72125.537.3818.7720.88
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
6064657587102128149117122115135126
53575865779011313110110394113101
Operating Profit6679101215181618212224
OPM %10.80%10.04%11.30%12.63%11.99%11.89%11.55%11.93%13.52%15.12%18.42%16.25%19.46%
24531447656158
Interest1111000000000
Depreciation1111111111122
Profit before Tax68910101517232022253432
Tax %28.15%22.96%25.21%26.22%24.46%25.19%24.68%24.08%22.38%24.68%24.63%25.31%22.96%
Net Profit000081113181617192525
0.070.080.090.100.110.160.140.190.210.180.230.270.26

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2022Mar 2023Mar 2024Mar 2025TTM
115151173184185220224263465498
104135155167168200204234411412
Operating Profit11161817172020305486
OPM %9.27%10.75%10.50%9.06%8.96%9.12%8.87%11.26%11.64%17.28%
111331215141733
Interest1000023411
Depreciation3333345557
Profit before Tax81416161626273466113
Tax %33.06%33.10%37.60%35.68%33.65%24.39%24.47%25.44%24.54%24.37%
Net Profit691010112020254986
EPS2.540.120.130.130.140.230.240.270.53—
Dividend Payout %23.66%16.76%16.00%15.07%14.83%13.07%0.00%0.00%0.00%—

COMPOUNDED SALES GROWTH

10 Years:
—
5 Years:
20%
3 Years:
28%

COMPOUNDED PROFIT GROWTH

10 Years:
—
5 Years:
37%
3 Years:
36%

STOCK PRICE CAGR

10 Years:
—
5 Years:
—
3 Years:
33%
1 Year:
8%

RETURN ON EQUITY

10 Years:
—
5 Years:
11%
3 Years:
11%
Last Year:
16%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2026

Sep 23

₹ 0.10

Rs.0.1000 per share(10%)Final Dividend

2022

Sep 9

₹ 0.03

Rs.0.0300 per share(3%)Final Dividend

2017

Sep 21

₹ 0.02

Rs.0.0200 per share(2%)Dividend

2016

Sep 22

₹ 0.02

Rs.0.0200 per share(2%)Dividend

2015

Sep 16

₹ 0.02

Rs.0.0200 per share(2%)Dividend

Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2022Mar 2023Mar 2024Mar 2025
Equity Capital227878787886949494
6517223139131162194248
4366135985746
Trade Payables192920473214202443
131616192118172025
Total Liabilities124144143181184308378407416
505046465547437278
Capital Work in Progress0005062600
796233643646693
61011151020212141
00000680103108
Cash & Bank4576709681
57697386761252157696
Total Assets124144143181184308378407416

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2022Mar 2023Mar 2024Mar 2025
811730182317-623
Cash from Investing-0-41-23-18-27-4583-18
Cash from Financing-6-11-25835-15-68
-121-11-2163-63

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2022Mar 2023Mar 2024Mar 2025

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
50.5750.5750.5750.5750.5750.5750.5750.5750.57
0.090.100.130.110.410.100.260.210.35
DIIs0.000.000.000.000.000.000.000.000.00
Government0.000.000.000.000.000.000.000.000.00
49.3449.3349.3049.3249.0249.3349.1749.2149.08

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-08
Copy of Newspaper Publication

2026-09-08 - Syncom Formulations (India) Limited has informed the Exchange about Copy of Newspaper Publication

2026-09-07
General Updates

2026-09-07 - Syncom Formulations (India) Limited has informed the Exchange about General Updates

2026-09-07
General Updates

2026-09-07 - Syncom Formulations (India) Limited has informed the Exchange about General Updates

2026-09-07
Shareholders meeting

2026-09-07 - Syncom Formulations (India) Limited has informed the Exchange about Shareholders meeting

2026-09-01
Copy of Newspaper Publication

2026-09-01 - Syncom Formulations (India) Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-13
General Updates

2026-08-13 - Syncom Formulations (India) Limited has informed the Exchange about General Updates

2026-08-13
Disclosure of material issue

2026-08-13 - Syncom Formulations (India) Limited has informed regarding Disclosure of material issue

2026-08-13
Disclosure of material issue

2026-08-13 - Syncom Formulations (India) Limited has informed regarding Disclosure of material issue

2026-08-12
Copy of Newspaper Publication

2026-08-12 - Syncom Formulations (India) Limited has informed the Exchange about Copy of Newspaper Publication

News

Recent coverage and analyst commentary for SYNCOMF

Loading news…

🤖

AI Stock Analyst

Syncom Formulations (India) Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login